Various Topics

Journal of Urban Health

, Volume 79, Issue 4, pp 579-585

First online:

Case-reporting of acute hepatitis B and C among injection drug users

  • Holly HaganAffiliated withUniversity of WashingtonPublic Health-Seattle and King CountyCenter for Drug Use and HIV Research, National Development and Research Institutes Email author 
  • , Nadine SnyderAffiliated withPublic Health-Seattle and King County
  • , Eillen HoughAffiliated withPublic Health-Seattle and King County
  • , Tianji YuAffiliated withPublic Health-Seattle and King County
  • , Shelly McKeirnanAffiliated withPublic Health-Seattle and King County
  • , Janice BoaseAffiliated withPublic Health-Seattle and King County
  • , Jeffrey DuchinAffiliated withPublic Health-Seattle and King CountyUniversity of Washington

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Although public health surveillance system data are widely used to describe the epidemiology of communicable disease, occurrence of hepatitis B and C virus (HBV and HCV, respectively) infections may be misrepresented by under-reporting in injection drug users (IDUs). This study was carried out to examine the relationship between HBV and HCV incidence and case-reporting of hepatitis B and C in Seattle IDUs. Names of participants in a Seattle IDU cohort study who acquired HBV or HCV infection over a 12-month follow-up period were compared to a database of persons with acute bepatitis B and C reported to the bealth department surveillance unit over the same period. Of 2,208 IDUs enrolled in the cohort who completed a follow-up visit, 63/759 acquired HBV infection, 53/317 acquired HCV infection, and 3 subjects acquired both HBV and HCV. Of 113 cohort subjects who acquired HBV or HCV, only 2 (1.5%) cases were reported; both bad acute bepatitis B. The upper 95% confidence limit for case-reporting of bepatitis C in the cohort was 5.7%, and for hepatitis B, it was 7.5%. In this study, reporting of acute bepatitis in IDUs was extremely low, raising questions regarding the use of community surveillance data to estimate underlying incidence in that population group.

Keywords

Hepatitis B Hepatitis C Substance use Surveillance